Skip to main content
Home

Main navigation

  • Home
  • News
  • About HIV
  • About us
  • Donate
Search
Donate now

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you.

I am a UK taxpayer and I understand that if I pay less Income and /or Capital Gains Tax than the amount of Gift Aid claimed on all my donations in the relevant tax year, it is my responsibility to pay any difference.

In our 35th year we’re asking people to donate £35 – that’s just £1 for every year we’ve been providing life-changing information. Any donation you make helps us continue our work towards a world where HIV is no longer a threat to health or happiness.

  • £5 allows us to reach millions of people globally with accurate and reliable resources about HIV prevention and treatment.
  • £10 helps us produce news and bulletins on the latest developments in HIV for healthcare staff around the world.
  • £35 means we can empower more people living with HIV to challenge stigma with our information workshops, videos and broadcasts.
Conferences

ICAAC 2012

The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012), was held in San Francisco, USA, 9-12th September 2012.
New & experimental hepatitis C treatment

Sofosbuvir appears safe and effective for HIV/HCV co-infected people

13 September 2012
Cardiovascular disease

HIV-positive people have heart attacks younger but receive later care

10 September 2012
Hepatitis B

Switching to tenofovir suppresses hepatitis B in HIV/HBV co-infected people

20 September 2012
New & experimental HIV treatments

Long-acting integrase inhibitor S/GSK1265744 active against multiple HIV subtypes

17 September 2012
New & experimental HIV treatments

Dolutegravir combo beats Atripla for effectiveness and tolerability

14 September 2012
Cancer

Progression of anal neoplasia is common among gay men with HIV

13 September 2012
New & experimental HIV treatments

Integrated analysis shows 'Quad' pill has potent activity with fewer side-effects

12 September 2012
Hepatitis B

Hepatitis B vaccine is effective for up to 15 years

12 September 2012
New & experimental HIV treatments

Long-acting fusion inhibitor albuvirtide looks promising in early studies

11 September 2012
Sign up for our email bulletins.
Sign up

Editors’ picks from other sources

New & experimental HIV treatments

Stribild (a.k.a. "Quad") Performs Well for People Over 50, Study Finds

Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) performs similarly among people over 50 years old as with younger people, according to the results of a two-study sub-analysis presented at ICAAC 2012. The presentation marks part of an emerging trend in research that reflects the aging of the HIV-infected population in the U.S., and the need for more studies on antiretrovirals specifically within older groups.
The Body
24 Sep 12
New & experimental HIV treatments

New HIV Drugs Promising but Unworkable

A new series of nucleotide competing reverse transcriptase inhibitors (NcRTIs) may represent a novel treatment option for HIV-1 infected patients but may be limited by toxicity given early animal data.
MedPage Today
14 Sep 12
New & experimental HIV treatments

Long-Lasting HIV Drug Could Change Therapy

An extremely long-lasting anti-HIV drug has the potential to alter both treatment and prevention of the virus, researchers said at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy. The investigational integrase inhibitor S/GSK744 might need to be given only every 3 months.
MedPage Today
13 Sep 12
People with limited treatment options

Booster HIV Drug Can Be Dropped

In a randomized trial, switching away from the booster drug allowed treatment-experienced patients to keep HIV under control and reduced toxicity, according to David Wohl, MD, of the University of North Carolina in Chapel Hill.
MedPage Today
13 Sep 12
Opportunistic infections

Ganciclovir Cuts CMV Organ Damage in HIV

Preemptive therapy dramatically reduced the risk of cytomegalovirus (CMV) end-organ damage in patients with HIV, researchers reported here.
MedPage Today
13 Sep 12
Adherence

Combo Pills Fail to Get More HIV Patients on Meds

An insurance database study found that HIV-infected patients who were not adherent to taking any antiretrovirals behaved that way regardless of whether they received single-pill or multiple-pill regimens.
MedPage Today
12 Sep 12
More editors' picks

About us

Our information is intended to support, rather than replace, consultation with a healthcare professional.

Talk to your doctor or another member of your healthcare team for advice tailored to your situation.

Connect with us

  • Twitter
  • Facebook
  • YouTube
  • Instagram

Links

Show — Links Hide — Links
  • Contact us
  • THT Direct Helpline
  • Subscribe to email bulletins

 

aidsmap (previously known as NAM aidsmap) is now hosted by Terrence Higgins Trust, an HIV charity based in the United Kingdom.

 

Copyright 2025 © Terrence Higgins Trust is a registered charity in England and Wales (reg. no. 288527) Company reg. no. 1778149 and a registered charity in Scotland (reg. no. SC039986). Registered office: 437 & 439 Caledonian Road, London, N7 9BG.

Footer menu

Show — Footer menu Hide — Footer menu
  • Accessibility
  • Compliment, complaint or concern
  • Our information
  • Privacy & cookies
  • Terms of use
  • Terrence Higgins Trust